Actively Recruiting
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Led by Charles Drew University of Medicine and Science · Updated on 2026-04-15
99
Participants Needed
1
Research Sites
122 weeks
Total Duration
On this page
Sponsors
C
Charles Drew University of Medicine and Science
Lead Sponsor
N
National Institute on Minority Health and Health Disparities (NIMHD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination. Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.
CONDITIONS
Official Title
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form and HIPPA authorization
- Willingness to comply with all study procedures and availability for the study duration
- Male patients 18 years or older
- Diagnosed with metastatic prostate cancer
- History of confirmed progressive disease with medical or surgical castration
- Confirmed progressive disease with concurrent use of enzalutamide, apalutamide, darolutamide, and/or abiraterone acetate
- Clinical decision to start docetaxel infusion with prednisone treatment
- Adequate bone marrow function (ANC >1500 cells/mm, platelet count >100,000 cells/mm)
- Adequate liver function (total bilirubin < ULN, ALT <1.5 x ULN, AST <1.5 x ULN)
- Adequate renal function (normal serum creatinine)
- At least 6 months or greater life expectancy
- Willing to stop consuming tea or tea-containing products and quercetin supplements during the intervention except study-provided green tea extract and quercetin
You will not qualify if you...
- Prior chemotherapy and/or radiotherapy for metastatic disease
- Any comorbid condition preventing docetaxel/prednisone administration
- Ongoing alcohol abuse
- Significant medical or psychiatric conditions making the patient a poor protocol candidate
- Prior allergic reaction to tea, tea products, or quercetin supplements
- Allergies to multiple food items or nutritional supplements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Charles R. Drew University of Medicine and Science
Los Angeles, California, United States, 90059
Actively Recruiting
Research Team
P
Piwen Wang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here